

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
69866-2005-03	Nexobrid (anacaulase bcdh) for topical gel. Active Ingredient: proteolytic enzymes extracted from the stems of pineapples Drug Strength: For topical gel: 8.8%; off-white to light tan lyophilized powder in a glass vial to be mixed in a clear and colorless gel vehicle in a glass jar. Size 5g.	1/16/2023

WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
<p>\$ 3,150.00</p>	<p>The Company conducted extensive market research with burn centers and evaluated other eschar removal options in its pricing analysis. Based on this analysis, the value of the Product justifies the WAC price.</p> <p>Product promotion designed to educate health care professionals will occur during medical conferences and during scheduled appointments with company representatives. Product information and product demonstration will be offered at industry conferences and at individual burn centers at the request of health care professionals.</p>	<p>Y</p>

ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
25500.00	N	N

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
5/7/2019	\$ 17,500,000.00	N

ACQUISITION PRICE COMMENT

The agreement states an upfront payment of \$17.5 million, with an additional \$7.5 million payment contingent upon U.S. approval and up to \$125 million contingent upon meeting certain annual sales milestones.

GENERAL COMMENTS